Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma

Akihiro Miyazaki, Noriyuki Sato, Shuji Takahashi, Aya Sasaki, Gen Iku Kohama, Akira Yamaguchi, Atsuhito Yagihashi, Kokichi Kikuchi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Although CD8+ killer T cells reacting against human autologous tumor cells have recently been studied in detail, little is known about the cytotoxic mechanism of CD4+ T cells against such tumor cells. In order to investigate this, we have established CD4+ cytotoxic T lymphocyte TcOSC-20 lines. TcOSC-20 showed selective cytotoxic activity against autologous OSC-20 cells, derived from a cancer of the tongue, in an HLA-DR-restricted fashion. HLA-DR8 (DRB1(*)08032) is the only DR molecule expressed on OSC-20 cells, and anti-DR8 monoclonal antibody could inhibit the cytotoxicity, suggesting that HLA-DRB1(*)08032 is the tumor rejection antigen-presenting molecule to TcOSC-20. The Fas ligand was expressed on TcOSC-20 lines, and its expression was induced upon mixed lymphocyte-tumor cell culture of autologous peripheral blood lymphocytes. Furthermore, the cytotoxicity of TcOSC-20 was inhibited by anti-Fas ligand antibody. These data imply that TcOSC-20 lines recognize the tumor antigenic peptide presented by HLA-DR8, and exert cytotoxicity against autologous tumor cells via a Fas-mediated cytotoxic pathway.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalJapanese Journal of Cancer Research
Volume88
Issue number2
Publication statusPublished - 1997
Externally publishedYes

Fingerprint

Histocompatibility Antigens
HLA Antigens
Squamous Cell Carcinoma
T-Lymphocytes
HLA-DRB1 Chains
Fas Ligand Protein
Neoplasms
Lymphocytes
Tongue Neoplasms
Cytotoxic T-Lymphocytes
HLA-DR Antigens
Neoplasm Antigens
Cell Culture Techniques
Monoclonal Antibodies
Peptides
Antibodies

Keywords

  • Autologous tumor
  • Fas antigen
  • HLA-DR8
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miyazaki, A., Sato, N., Takahashi, S., Sasaki, A., Kohama, G. I., Yamaguchi, A., ... Kikuchi, K. (1997). Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma. Japanese Journal of Cancer Research, 88(2), 191-197.

Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma. / Miyazaki, Akihiro; Sato, Noriyuki; Takahashi, Shuji; Sasaki, Aya; Kohama, Gen Iku; Yamaguchi, Akira; Yagihashi, Atsuhito; Kikuchi, Kokichi.

In: Japanese Journal of Cancer Research, Vol. 88, No. 2, 1997, p. 191-197.

Research output: Contribution to journalArticle

Miyazaki, A, Sato, N, Takahashi, S, Sasaki, A, Kohama, GI, Yamaguchi, A, Yagihashi, A & Kikuchi, K 1997, 'Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma', Japanese Journal of Cancer Research, vol. 88, no. 2, pp. 191-197.
Miyazaki, Akihiro ; Sato, Noriyuki ; Takahashi, Shuji ; Sasaki, Aya ; Kohama, Gen Iku ; Yamaguchi, Akira ; Yagihashi, Atsuhito ; Kikuchi, Kokichi. / Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma. In: Japanese Journal of Cancer Research. 1997 ; Vol. 88, No. 2. pp. 191-197.
@article{f26c6889674249b498b86bdc7805e063,
title = "Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma",
abstract = "Although CD8+ killer T cells reacting against human autologous tumor cells have recently been studied in detail, little is known about the cytotoxic mechanism of CD4+ T cells against such tumor cells. In order to investigate this, we have established CD4+ cytotoxic T lymphocyte TcOSC-20 lines. TcOSC-20 showed selective cytotoxic activity against autologous OSC-20 cells, derived from a cancer of the tongue, in an HLA-DR-restricted fashion. HLA-DR8 (DRB1(*)08032) is the only DR molecule expressed on OSC-20 cells, and anti-DR8 monoclonal antibody could inhibit the cytotoxicity, suggesting that HLA-DRB1(*)08032 is the tumor rejection antigen-presenting molecule to TcOSC-20. The Fas ligand was expressed on TcOSC-20 lines, and its expression was induced upon mixed lymphocyte-tumor cell culture of autologous peripheral blood lymphocytes. Furthermore, the cytotoxicity of TcOSC-20 was inhibited by anti-Fas ligand antibody. These data imply that TcOSC-20 lines recognize the tumor antigenic peptide presented by HLA-DR8, and exert cytotoxicity against autologous tumor cells via a Fas-mediated cytotoxic pathway.",
keywords = "Autologous tumor, Fas antigen, HLA-DR8, Squamous cell carcinoma",
author = "Akihiro Miyazaki and Noriyuki Sato and Shuji Takahashi and Aya Sasaki and Kohama, {Gen Iku} and Akira Yamaguchi and Atsuhito Yagihashi and Kokichi Kikuchi",
year = "1997",
language = "English",
volume = "88",
pages = "191--197",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Cytotoxicity of histocompatibility leukocyte Antigen-DR8-restricted CD4+ killer T cells against human autologous squamous cell carcinoma

AU - Miyazaki, Akihiro

AU - Sato, Noriyuki

AU - Takahashi, Shuji

AU - Sasaki, Aya

AU - Kohama, Gen Iku

AU - Yamaguchi, Akira

AU - Yagihashi, Atsuhito

AU - Kikuchi, Kokichi

PY - 1997

Y1 - 1997

N2 - Although CD8+ killer T cells reacting against human autologous tumor cells have recently been studied in detail, little is known about the cytotoxic mechanism of CD4+ T cells against such tumor cells. In order to investigate this, we have established CD4+ cytotoxic T lymphocyte TcOSC-20 lines. TcOSC-20 showed selective cytotoxic activity against autologous OSC-20 cells, derived from a cancer of the tongue, in an HLA-DR-restricted fashion. HLA-DR8 (DRB1(*)08032) is the only DR molecule expressed on OSC-20 cells, and anti-DR8 monoclonal antibody could inhibit the cytotoxicity, suggesting that HLA-DRB1(*)08032 is the tumor rejection antigen-presenting molecule to TcOSC-20. The Fas ligand was expressed on TcOSC-20 lines, and its expression was induced upon mixed lymphocyte-tumor cell culture of autologous peripheral blood lymphocytes. Furthermore, the cytotoxicity of TcOSC-20 was inhibited by anti-Fas ligand antibody. These data imply that TcOSC-20 lines recognize the tumor antigenic peptide presented by HLA-DR8, and exert cytotoxicity against autologous tumor cells via a Fas-mediated cytotoxic pathway.

AB - Although CD8+ killer T cells reacting against human autologous tumor cells have recently been studied in detail, little is known about the cytotoxic mechanism of CD4+ T cells against such tumor cells. In order to investigate this, we have established CD4+ cytotoxic T lymphocyte TcOSC-20 lines. TcOSC-20 showed selective cytotoxic activity against autologous OSC-20 cells, derived from a cancer of the tongue, in an HLA-DR-restricted fashion. HLA-DR8 (DRB1(*)08032) is the only DR molecule expressed on OSC-20 cells, and anti-DR8 monoclonal antibody could inhibit the cytotoxicity, suggesting that HLA-DRB1(*)08032 is the tumor rejection antigen-presenting molecule to TcOSC-20. The Fas ligand was expressed on TcOSC-20 lines, and its expression was induced upon mixed lymphocyte-tumor cell culture of autologous peripheral blood lymphocytes. Furthermore, the cytotoxicity of TcOSC-20 was inhibited by anti-Fas ligand antibody. These data imply that TcOSC-20 lines recognize the tumor antigenic peptide presented by HLA-DR8, and exert cytotoxicity against autologous tumor cells via a Fas-mediated cytotoxic pathway.

KW - Autologous tumor

KW - Fas antigen

KW - HLA-DR8

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0030937570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030937570&partnerID=8YFLogxK

M3 - Article

C2 - 9119748

AN - SCOPUS:0030937570

VL - 88

SP - 191

EP - 197

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 2

ER -